Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Market Outlook

Thelansis’s “Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Overview

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an immune-mediated demyelinating disorder that affects the central nervous system by causing inflammation and damage to the optic nerve, spinal cord, brain, and/or brainstem. The MOG protein is found in the nerve coverings of the central nervous system and is involved in myelin maturation and cell surface interactions. The exact cause of MOGAD is unknown, and it affects males and females equally but is more prevalent in children than adults. The symptoms of MOGAD are categorized into optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), and cerebral encephalitis. Diagnosing MOGAD requires a blood test to screen for antibodies and MRI and lumbar puncture.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers

• Physician surveys

• RWE analysis for claims and EHR datasets

• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)

• Market Forecast Model (MS Excel-based automated dashboard)

• Epidemiology (MS Excel; interactive tool)

• Executive Insights (PowerPoint presentation)

• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)

• Bottom-up patient-based market forecasts validated through the top-down sales methodology

• Covers clinically and commercially-relevant patient populations/ line of therapies

• Annualized drug-level sales and patient share projections

• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach

• Detailed methodology/sources & assumptions

• Graphical and tabular outputs

• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?

• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?

• What is the 10-year market outlook for sales and patient share?

• Which events will have the greatest impact on the market’s trajectory?

• What insights do interviewed experts provide on current and emerging treatments?

• Which pipeline products show the most promise, and what is their potential for launch and future positioning?

• What are the key unmet needs and KOL expectations for target profiles?

• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

• and more…

Read more: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034